|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
2020 Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs ... -release), CM-4612, methylphenidate sustained release, edivoxetine hydrochloride, ECH-201, PF8001, PF8026 ... Adrenergic uptake inhibitors - Pipeline Insight, 2022 ... , it is in phase 3 of development stage. Edivoxetine: Eli Lilly and Company Edivoxetine (LY-2216684) is an antidepressant produced ... Qrono Apnimed Key Products Ampreloxetine Edivoxetine Nolazol Amitifadine D 473 TAS 303 ... Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimer ... Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma 2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be 'decisive' in spurring generic penetration ... Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit ... TAKEDA , Challenges Ahead for its New European Presiden ... Enough Against Genericized MDD Market, Edivoxetine failure a moderate Positive- while development ... |